| scholarly article | Q13442814 |
| P2093 | author name string | Laurence Collette | |
| Xavier Paoletti | |||
| Maria-Athina Altzerinakou | |||
| P2860 | cites work | Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents. | Q30371414 |
| Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes | Q30868533 | ||
| Dose finding with longitudinal data: simpler models, richer outcomes | Q30976631 | ||
| Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper | Q31034415 | ||
| A semiparametric probit model for case 2 interval-censored failure time data | Q33523547 | ||
| CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment | Q35193958 | ||
| The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials | Q36295897 | ||
| Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials | Q37685787 | ||
| Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents | Q37723328 | ||
| Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs | Q39320891 | ||
| Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. | Q39910979 | ||
| A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes | Q42113412 | ||
| Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience. | Q43846394 | ||
| Dose-finding based on efficacy-toxicity trade-offs | Q45038149 | ||
| Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials | Q45274026 | ||
| A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial | Q45885052 | ||
| A Bayesian approach to dose-finding studies for cancer therapies: incorporating later cycles of therapy. | Q51105513 | ||
| An adaptive dose-finding design incorporating both toxicity and efficacy. | Q51962375 | ||
| Sequential designs for phase I clinical trials with late-onset toxicities | Q73326314 | ||
| Accelerated titration designs for phase I clinical trials in oncology | Q73598986 | ||
| Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT) | Q81341430 | ||
| Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? | Q83737803 | ||
| Phase 1 trials of molecular targeted therapies: are we evaluating toxicities properly? | Q84068888 | ||
| On the analysis of discrete time competing risks data | Q88388870 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 1179-1185 | |
| P577 | publication date | 2019-11-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose | |
| P478 | volume | 111 |
Search more.